Literature DB >> 21146122

Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy.

Mark A Perazella1, Gilbert W Moeckel.   

Abstract

Nephrotoxicity remains a vexing complication of chemotherapeutic agents. A number of kidney lesions can result from these drugs, including primarily tubular-limited dysfunction, glomerular injury with proteinuria, full-blown acute kidney injury, and long-term chronic kidney injury. In most cases, these kidney lesions develop from innate toxicity of these medications, but underlying host risk factors and the renal handling of these drugs clearly increase the likelihood of nephrotoxicity. This article reviews some of the classic nephrotoxic chemotherapeutic agents and focuses on examples of the clinical and histopathologic kidney lesions they cause as well as measures that may prevent or treat drug-induced nephrotoxicity.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21146122     DOI: 10.1016/j.semnephrol.2010.09.005

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  68 in total

Review 1.  Drug-induced acute kidney injury in children.

Authors:  Lauren N Faught; Michael J E Greff; Michael J Rieder; Gideon Koren
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

Review 2.  Pharmacology behind Common Drug Nephrotoxicities.

Authors:  Mark A Perazella
Journal:  Clin J Am Soc Nephrol       Date:  2018-04-05       Impact factor: 8.237

Review 3.  Kidney Organoids: A Translational Journey.

Authors:  Ryuji Morizane; Joseph V Bonventre
Journal:  Trends Mol Med       Date:  2017-02-07       Impact factor: 11.951

Review 4.  Kidney diseases associated with haematological cancers.

Authors:  Anirban Ganguli; Deirdre Sawinski; Jeffrey S Berns
Journal:  Nat Rev Nephrol       Date:  2015-06-02       Impact factor: 28.314

5.  Reduced kidney lipoprotein lipase and renal tubule triglyceride accumulation in cisplatin-mediated acute kidney injury.

Authors:  Shenyang Li; Kiran Nagothu; Gouri Ranganathan; Syed M Ali; Brian Shank; Neriman Gokden; Srinivas Ayyadevara; Judit Megyesi; Gunilla Olivecrona; Sumant S Chugh; Sander Kersten; Didier Portilla
Journal:  Am J Physiol Renal Physiol       Date:  2012-05-23

Review 6.  Management of nephrotoxicity of chemotherapy and targeted agents: 2020.

Authors:  Varsha Chiruvella; Pavan Annamaraju; Achuta K Guddati
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

Review 7.  Guidelines for treatment of renal injury during cancer chemotherapy 2016.

Authors:  Shigeo Horie; Mototsugu Oya; Masaomi Nangaku; Yoshinari Yasuda; Yasuhiro Komatsu; Motoko Yanagita; Yuko Kitagawa; Hiroyuki Kuwano; Hiroyuki Nishiyama; Chikashi Ishioka; Hiromasa Takaishi; Hideki Shimodaira; Akira Mogi; Yuichi Ando; Koji Matsumoto; Daisuke Kadowaki; Satoru Muto
Journal:  Clin Exp Nephrol       Date:  2018-02       Impact factor: 2.801

8.  Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center.

Authors:  Abdulla K Salahudeen; Simit M Doshi; Tushar Pawar; Gul Nowshad; Amit Lahoti; Pankaj Shah
Journal:  Clin J Am Soc Nephrol       Date:  2012-12-14       Impact factor: 8.237

9.  Nephrotoxin Microinjection in Zebrafish to Model Acute Kidney Injury.

Authors:  Robert A McKee; Rebecca A Wingert
Journal:  J Vis Exp       Date:  2016-07-17       Impact factor: 1.355

10.  Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity.

Authors:  Md Abdul Hye Khan; Jing Liu; Ganesh Kumar; Stephen X Skapek; John R Falck; John D Imig
Journal:  FASEB J       Date:  2013-04-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.